Figure 3From: Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)Pharmacokinetics of ITF2357 in healthy male subjects during seven daily doses. (A) Mean (± SD) plasma concentrations of ITF2357 after the first single oral dose are shown. (B) Mean (± SD) plasma ITF2357 on day 7 after seven daily doses. n = 8 in each group.Back to article page